Clinical trial · Interventional
Multiple-portal VATS Versus Uniportal VATS Lobectomy for Non-small Cell Lung Cancer
A Randomized Controlled Study: the Effect of Multiple-portal VATS Versus Conventional VATS Lobectomy for NSCLC
NCT02462356CI-TRIAL-00021757MVUVLCunknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study evaluate multiple-portal VATS and uniportal VATS lobectomy for NSCLC, half of participants will receive multiple VATS, while the other half will receive uniportal VATS lobectomy.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Non Small Cell Lung Cancer | Lung Non-Small Cell Carcinoma | ALIAS | 0.90 |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Conventional VATS | Procedure | — | UNRESOLVED |
| Uniportal VATS | Procedure | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- Conventional VATS
- description
- Via conventional VATS lobectomy and systematic lymph node dissection for lung cancer
- interventionNames
- Procedure: Conventional VATS
- type
- EXPERIMENTAL
- label
- Uniportal VATS
- description
- Via uniportal VATS lobectomy and systematic lymph node dissection for lung cancer
- interventionNames
- Procedure: Uniportal VATS
Primary outcomes (1)
- measure
- short-term quality of life(EQ5D) between the two groups
- timeFrame
- Up to 6 month
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 35 Years
- Maximum age
- 75 Years
Show eligibility criteria text
Inclusion Criteria: * Patients with clinical diagnosis of primary lung cancer with the age between 35 and 75 years old; * Patients with Tumor size ≤5cm,clinically staged T1-2N0-1M0,prepared for lobectomy and mediastinal lymph node dissection; * Patients with an American Society of Anesthesiology score of 0-1. Exclusion Criteria: * Patients with N2 or N3 positive or distant metastasis. * Patients who had undergone Neoadjuvant chemotherapy. * Patients with tumor invasion to the peripheral structures. * Patients with previous history of thoracic operations. * Patients with serious thoracic adhesion. * Patients who will undergo Pneumonectomy, sleeve lobectomy, segmentectomy, wedge resection. * Patients with preexisting chronic obstructive pulmonarydisease, asthma, or interstitial lung disease; * Patients with cardiac, hepatic, or renal dysfunction;
References
Publications (1)
- DERIVEDYao J, Chang Z, Zhu L, Fan J. Uniportal versus multiportal thoracoscopic lobectomy: Ergonomic evaluation and perioperative outcomes from a randomized and controlled trial. Medicine (Baltimore). 2020 Oct 16;99(42):e22719. doi: 10.1097/MD.0000000000022719. PMID 33080728